A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Must have received at least one dose of ALXN2220 in Study NI006-101
Locations
Other Locations
France
Hôpital Henri Mondor
RECRUITING
Créteil
CHU de Rennes - Hôpital Pontchaillou
RECRUITING
Rennes
CHU Toulouse - Hôpital Rangueil
RECRUITING
Toulouse
Germany
Universitätsklinikum Heidelberg
RECRUITING
Heidelberg
Netherlands
University Medical Center Groningen
RECRUITING
Groningen
Spain
Hospital Universitario Puerta de Hierro Majadahonda
RECRUITING
Majadahonda
Contact Information
Primary
Peter C. Kahr, MD
peter.kahr@neurimmune.com
+41 44 755 46 14
Backup
Julie Schwindenhammer
julie.schwindenhammer@neurimmune.com
+41 44 755 4670
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2026-10-31
Participants
Target number of participants: 35
Treatments
Experimental: ALXN2220
Participants will receive ALXN2220 via intravenous (IV) infusion during the Active Treatment Period
Related Therapeutic Areas
Sponsors
Leads: Neurimmune AG
Collaborators: Alexion Pharmaceuticals, Inc.